Travere Therapeutics, Inc. (TVTX) Fell Out Of Favor With Hedge Funds?
We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC.
Travere Therapeutics Inc. (TVTX)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 45,000,000 | $454,824 | 6.6% | ||
| 2. | 39,563,000 | $39,591 | +48% | 1.18% | |
| 3. | 29,436,000 | $29,515 | -1% | 0.02% | |
| 4. | 10,920,000 | $11,007 | +425% | 0.15% | |
| 5. | 5,905,000 | $5,993 | 0.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | Officer, Director | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | Director | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | Director | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | Director | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | Officer, Director | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.40 | 5,000 | Officer | 37,548 | 2022-01-11 | Filing | |
| $27.40 | 2,500 | Officer | 38,395 | 2022-01-11 | Filing | |
| $27.40 | 7,500 | Officer | 31,316 | 2022-01-11 | Filing | |
| $30.48 | 2,139 | Officer, Director | 139,583 | 2022-01-05 | Filing | |
| $29.84 | 10,361 | Officer, Director | 141,722 | 2022-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | Ubs Oconnor LlcBOND | 18,500,000 | $18,577,000 | 0.42% |
| 2. | 22,500,000 | $22,679 | 0.02% | |
| 3. | 20,845 | $21,012 | 2.14% | |
| 4. | 17,393,000 | $17,514 | 0.32% | |
| 5. | Citigroup IncBOND | 15,000,000 | $15,083 | 0% |
News See All
Do Hedge Funds Love Travere Therapeutics, Inc. (TVTX)?
In this article we will check out the progression of hedge fund sentiment towards Travere Therapeutics, Inc. (NASDAQ:TVTX) and determine whether it is a good investment right now.
5 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
In this article, we will discuss the 5 best biotech stocks to buy according to Joseph Edelman's Perceptive Advisors based on Q2 holdings of the fund.
Where Do Hedge Funds Stand On Travere Therapeutics, Inc. (TVTX)?
In this article we will analyze whether Travere Therapeutics, Inc.
5 Best Biotech Stocks to Invest In
A clinical-stage biopharmaceutical company Global Blood Therapeutics, Inc. (NASDAQ: GBT) is the long-running investment of a billionaire hedge fund manager.
Billionaire Hedge Funds
